Search jobs 20-Jan-2021 Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Mergers & Acquisitions
20.01.2021 / 07:00
Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil
Geneva, Switzerland, and Gundelfingen, Germany, January 20, 2021 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (
Relief ), a biopharmaceutical company with its lead compound RLF-100
TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, and AdVita Lifescience GmbH (
Search jobs 30-Dec-2020 Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
EQS Group-News: RELIEF THERAPEUTICS Holdings AG / Key word(s): Study
30.12.2020 / 07:00
Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure
Geneva, Switzerland and Radnor, Pa, USA, December 30, 2020 - RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (
Relief or the
Company ) and NeuroRx, Inc. today announced the conclusion of enrollment in the phase 2b/3 trial of ZYESAMI(TM) (previously RLF-100
TM: aviptadil) for the treatment of Respiratory Failure in patients with Critical COVID-19 (www.clinicaltrials.gov NCT04311697). No drug-related serious adverse events have been reported as of today. Enrollment was increased from 165 patients in order to amass as large a safety database as possible. Top
EQS-News: Relief and NeuroRx Conclude Enrollment in their Phase 2b/3 Trial of RLF-100(TM) for Critical COVID-19 with Respiratory Failure marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.